KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Deferred Taxes: 2012-2024

Historic Deferred Taxes for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Dec 2024 value amounting to -$20.1 million.

  • Supernus Pharmaceuticals' Deferred Taxes rose 59.10% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.9 million, marking a year-over-year increase of 54.56%. This contributed to the annual value of -$20.1 million for FY2024, which is 21.69% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Deferred Taxes stood at -$20.1 million for FY2024, which was up 21.69% from -$25.7 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Deferred Taxes high stood at $568,000 for FY2020, and its period low was -$26.3 million during FY2022.
  • For the 3-year period, Supernus Pharmaceuticals' Deferred Taxes averaged around -$24.1 million, with its median value being -$25.7 million (2023).
  • Its Deferred Taxes has fluctuated over the past 5 years, first surged by 109.74% in 2020, then crashed by 979.23% in 2021.
  • Over the past 5 years, Supernus Pharmaceuticals' Deferred Taxes (MRY) stood at $568,000 in 2020, then tumbled by 979.23% to -$5.0 million in 2021, then plummeted by 427.11% to -$26.3 million in 2022, then increased by 2.32% to -$25.7 million in 2023, then rose by 21.69% to -$20.1 million in 2024.
  • Its last three reported values are -$20.1 million in FY2024, -$25.7 million for FY2023, and -$26.3 million during FY2022.